(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 93.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Agios Pharmaceuticals's revenue in 2026 is $54,028,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $5,538,307,874, with the lowest AGIO revenue forecast at $3,847,162,014, and the highest AGIO revenue forecast at $7,167,580,401. On average, 12 Wall Street analysts forecast AGIO's revenue for 2027 to be $14,718,939,528, with the lowest AGIO revenue forecast at $9,048,389,122, and the highest AGIO revenue forecast at $21,523,834,384.
In 2028, AGIO is forecast to generate $22,933,562,043 in revenue, with the lowest revenue forecast at $16,559,905,572 and the highest revenue forecast at $29,333,584,990.